PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)--
Rosetta Genomics Ltd. (NASDAQ:ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces that the United States Patents and Trademark Office (USPTO) has granted two patent allowances for patent applications US 14/756,185 (‘185) and US 14/999,879 (‘879), both divisional patents of the parent application titled “microRNAs and uses thereof.”
Application ‘185 claims hsa-miR-146-5p, its complement and a sequence at least 95% identical to it, as well as a probe and a vector comprising this microRNA. Application ‘879 claims hsa-miR-551b-3p, its complement and a sequence of at least 18 nucleotides identical to it, as well as a probe and a vector comprising this microRNA.
“We are especially pleased with these two patent allowances as they are important markers for our RosettaGX RevealTM thyroid cancer assay, and both have been confirmed as valuable markers by independent researchers in the field of thyroid cancer,” stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “We are creating a strong intellectual property position in microRNAs and thyroid cancer diagnostics. Of note, there are approximately 500 peer-reviewed publications that confirm the effectiveness of microRNAs as biomarkers in the diagnosis of thyroid cancer which makes these and other microRNAs in our RosettaGX RevealTM assay potentially even more valuable. We believe there may be opportunities to monetize this and other intellectual property pursuant to outlicenses to others working in this field. We are pursuing additional patents for our Reveal assay and look forward to their issuance. Our solid patent position, along with Reveal’s numerous competitive advantages including the ability to work off of routinely prepared FNA smears, creates the opportunity for significant revenue growth this year and well into the future.”
About Rosetta Genomics
Rosetta is pioneering the field of molecular diagnostics by offering rapid and accurate diagnostic information that enables physicians to make more timely and informed treatment decisions to improve patient care. Rosetta has developed a portfolio of unique diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists and other specialists to help them deliver better care to their patients. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of cancer in thyroid nodules, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company’s Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs.
Forward-Looking Statement Disclaimer
Various statements in this release, including but not limited to, statements relating to monetizing or out licensing intellectual property, securing additional patents, and accelerating revenue growth constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta’s most recently filed Annual Report on Form 20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170206005294/en/
